There is substantial evidence in the literature that elevated plasma
free fatty acids (FFA) play a role in the pathogenesis of
type 2 diabetes.
CVT-3619 is a selective partial A(1)
adenosine receptor agonist that inhibits lipolysis and lowers circulating FFA. The present study was undertaken to determine the effect of
CVT-3619 on
insulin resistance induced by high-fat (HF) diet in rodents. HF diet feeding to rats for 2 wk caused a significant increase in
insulin, FFA, and
triglyceride (TG) concentrations compared with rats fed chow.
CVT-3619 (1 mg/kg) caused a time-dependent decrease in fasting
insulin, FFA, and TG concentrations. Acute administration of
CVT-3619 significantly lowered the
insulin response, whereas
glucose response was not different with an oral
glucose tolerance test. Treatment with
CVT-3619 for 2 wk resulted in significant lowering of FFA, TG, and
insulin concentrations in rats on HF diet. To determine the effect of
CVT-3619 on
insulin sensitivity, hyperinsulinemic euglycemic clamp studies were performed in C57BL/J6 mice fed HF diet for 12 wk.
Glucose infusion rate was decreased significantly in HF mice compared with chow-fed mice.
CVT-3619 treatment 15 min prior to the clamp study significantly (P < 0.01) increased
glucose infusion rate to values similar to that for chow-fed mice. In conclusion,
CVT-3619 treatment lowers FFA and TG concentrations and improves
insulin sensitivity in rodent models of
insulin resistance.